PHAT - NASDAQ

Phathom Pharmaceuticals, Inc.

PHAT·NASDAQ

$9.94

+3.0%

HealthcareBiotechnology

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$792.77M

EPS-3.0300

P/E Ratio-3.28

Earnings Date08/06/2026

259.15M

Assets

-31%

3Y+57.0%

5Y-12.0%

10Y+28630.0%

697.32M

Total Liabilities

10%

3Y+191.0%

5Y+592.0%

10Y+31770.0%

-438.17M

Total Equity

73%

3Y+486.0%

5Y-326.0%

10Y+33972.0%

Phathom Pharmaceuticals, Inc. Funding & Solvency Profile

PHAT · NASDAQ

Current Assets

Cash & Cash Equivalents129.97M

Net Receivables78.13M

Inventory5.52M

Other Current Assets15.35M

Total Current Assets229 M

Non-Current Assets

Property, Plant & Equipment3.67M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets26.51M

Total Non-Current Assets30 M

Total Assets

259.15M

Financial Health Analysis

Current Ratio

1.73x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Working Capital

97 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

88% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Phathom Pharmaceuticals, Inc. Balance Sheet

PHAT • NASDAQ

Phathom Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	130M	297.3M	381.4M	155.4M	183.3M	287.5M	243.8M	879K
Cash & Short-Term Investments	130M	297.3M	381.4M	155.4M	183.3M	287.5M	243.8M	879K
Net Receivables	78.1M	38.8M	1.6M	0.0	0.0	82K	0.0	0.0
Accounts Receivables	78.1M	38.8M	1.6M	0.0	0.0	82K	0.0	0.0
Inventory	5.5M	3.2M	1.2M	0.0	0.0	-82K	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4K
Other Current Assets	15.4M	20.9M	13.2M	5.1M	3.3M	3.9M	11.8M	0.0
Total Current Assets	229M	360.1M	397.4M	160.5M	186.5M	291.4M	255.6M	902K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.7M	2.1M	3.6M	3.5M	2.6M	3.4M	1.4M	0.0
Long-Term Investments	0.0	2.9M	0.0	505K	0.0	0.0	0.0	0.0
Other Non-Current Assets	26.5M	13.2M	12.8M	299K	341K	384K	181K	0.0
Total Non-Current Assets	30.2M	18.2M	16.4M	4.3M	2.9M	3.7M	1.6M	0.0
Total Assets	259.1M	378.3M	413.8M	164.8M	189.4M	295.1M	257.2M	902K
LIABILITIES
CURRENT LIABILITIES
Total Payables	5M	10.5M	12.6M	10M	5.2M	16.8M	699K	55K
Accounts Payable	5M	10.5M	12.6M	10M	5.2M	16.8M	699K	55K
Accrued Expenses	0.0	0.0	5M	15.5M	13.3M	30.9M	1.4M	183K
Short Term Debt	648K	19.8M	0.0	0.0	0.0	7.4M	161K	2M
Capital Lease Obligations (Current)	0.0	501K	726K	708K	487K	474K	161K	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	2.5M	-2M
Other Current Liabilities	126.4M	54.9M	20.4M	0.0	0.0	0.0	1.3M	0.0
Total Current Liabilities	132M	85.7M	38.8M	26.2M	18.9M	55.5M	3.7M	2.2M
NON-CURRENT LIABILITIES
Long Term Debt	2.1M	534.7M	137.8M	95.3M	89.7M	39.6M	22.8M	0.0
Other Non-Current Liabilities	563.2M	11.5M	309.5M	117M	7.5M	4.1M	2.1M	0.0
Total Non-Current Liabilities	565.3M	546.2M	447.8M	213.4M	98.4M	45.3M	25.5M	0.0
Capital Lease Obligations	0.0	501K	1.2M	1.8M	1.7M	2M	796K	0.0
Total Liabilities	697.3M	631.9M	486.6M	239.6M	117.3M	100.8M	29.2M	2.2M
SHAREHOLDERS' EQUITY
Common Stock	6K	6K	5K	3K	3K	3K	2K	0.0
Additional Paid-In Capital	0.0	1B	855.9M	652.3M	601.5M	579.8M	484.4M	2K
Retained Earnings	-1.5B	-1.3B	-928.7M	-727.1M	-529.4M	-385.5M	-256.4M	-1.3M
Other Total Stockholders' Equity	1B	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	-438.2M	-253.6M	-72.8M	-74.8M	72.2M	194.3M	228M	-1.3M
Total Equity	-438.2M	-253.6M	-72.8M	-74.8M	72.2M	194.3M	228M	-1.3M
SUMMARY
Total Liabilities & Equity	259.1M	378.3M	413.8M	164.8M	189.4M	295.1M	257.2M	902K
Total Investments	0.0	2.9M	0.0	505K	0.0	0.0	0.0	0.0
Total Debt	2.7M	554.9M	139M	97.1M	91.3M	49M	23.6M	2M
Net Debt	-127.3M	257.7M	-242.4M	-58.3M	-91.9M	-238.5M	-220.2M	1.1M
Shares Outstanding	71,134,736	71,134,736	71,134,736	71,134,736	71,134,736	71,134,736	71,134,736	71,134,736

SEC Filings

PHAT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 19, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 07, 2026	May 19, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 30, 2025	2025	View Filing

Showing 1 to 10 of 137 filings

Related Guides

Blog Categories

Continue your PHAT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.